GlassScriptPhysician profile
Keith P Burwell
NPI 1215298716
$14,210.82
in general payments reported to CMS, 2019-2025
41 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $749 · 2021: $1,799 · 2022: $2,386 · 2023: $2,436 · 2024: $2,358 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,004 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,004.23 |
| Education | $289.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,968.03 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,941.99 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $1,897.63 | 2019-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $1,188.45 | 2019-2025 | |
| Ucb, INC. | $1,050.94 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $894.28 | 2019-2025 | |
| Lilly USA, LLC | $822.11 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $665.38 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $526.36 | 2019-2025 | Orencia |
| Radius Health, INC. | $482.75 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $346.40 | 2019-2025 | Actemra, Gazyva |
| Glaxosmithkline, LLC. | $343.44 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $286.28 | 2022-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $254.36 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $154.30 | 2024-2025 | Idacio |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Burwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.